10.21.20
Ferring Pharmaceuticals to Present New Microbiome Research Data at IDWeek 2020
Download PDF
05.06.20
Rebiotix and Ferring Announce World’s First with Positive Preliminary Pivotal Phase 3 Data for Investigational Microbiome-based Therapy RBX2660
02.04.20
Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660
08.21.19
Rebiotix, Inc. and Karolinska Institutet Expand Partnership to Shape the Future of Microbiome Research
06.26.19
Rebiotix Leaders to Discuss Microbiome Product Development Challenges and Regulation at Microbiome Movement – Drug Development Summit 2019
06.14.19
Statement: Response to FDA Safety Alert Regarding the Use of Fecal Microbiota for Transplantation
05.17.19
Microbiota Restoration Takes the Podium at DDW 2019: Investigational Microbiota-Based Therapies for Recurrent C. diff Highlighted
03.20.19
MICROBIOME HEALTH INDEX™ Platform to be Presented at Gut Microbiota for Health Summit 2019
11.01.18
Rebiotix, C. Diff Foundation Commend State of Minnesota for Declaring November Clostridium difficile Awareness Month
10.22.18
Rebiotix MICROBIOME HEALTH INDEX™ Data to be Presented at United European Gastroenterology Annual Conference
10.03.18
Baylor, Rebiotix Find Patient Microbiome Signatures That Differentiate Disease States
10.01.18
Rebiotix Clinical, Microbiome Data from First-In-Class Microbiota Restoration Therapy to Be Presented at IDWeek 2018
06.08.18
MICROBIOME HEALTH INDEX™ Platform, Outcomes of Rebiotix’s RBX7455 Oral Formulation To Be Featured in Rapid Fire and Poster Sessions at ASM Microbe 2018
06.04.18
Rebiotix Microbiota Restoration Therapy™ Products, MICROBIOME HEALTH INDEX™ to Take Center Stage at Digestive Disease Week 2018
06.01.18
Rebiotix’s President and CEO, Lee Jones to Participate in Microbiome-Focused Panel at the 2018 BIO International Convention
04.24.18
Rebiotix Presents Posters at ECCMID 2018 Highlighting MICROBIOME HEALTH INDEX™ Value Potential and RBX2660 Phase 2 Clinical Program Data
04.05.18
Ferring Acquires Innovative Biotechnology Company and Microbiome Pioneer Rebiotix Inc.
03.27.18
Rebiotix’s Lee Jones to Receive TRUST 2018 Courageous Women in Health Care Award
03.12.18
Rebiotix’s Chief Scientific Officer, Ken Blount, Ph.D., to Present at Microbiome Therapeutics Europe
02.12.18
Rebiotix Develops MICROBIOME HEALTH INDEX™ to Identify Indicators for Microbiome Restoration
01.09.18
Rebiotix Highlights 2017 Achievements and 2018 Objectives
01.05.18
Rebiotix and CoreBiome Collaborate on Evaluating Microbiomes of Patients Treated with Microbiota Restoration Therapy™
01.04.18
Rebiotix Participating in Multiple Events During J.P. Morgan 36th Annual Healthcare Conference 2018 Week
11.29.17
Rebiotix Announces Expansion of Phase 1 Trial of the Company’s Oral Capsule Microbiota Product, RBX7455, Following Successful Completion of Initial Study Arms
11.15.17
Rebiotix to Present at 29th Annual Piper Jaffray Healthcare Conference
11.02.17
Rebiotix and the C Diff Foundation Applaud the State of Minnesota as it Declares November C. Difficile Infection Awareness Month
10.16.17
New Clinical Data and Microbiome Research from Rebiotix’s Phase 2 Program for RBX2660 Highlighted at the World Congress of Gastroenterology at ACG2017
10.12.17
Rebiotix Announces New RBX2660 Data Including a Novel Microbiome Biomarker Analysis to be Presented at the World Congress of Gastroenterology at ACG2017
10.04.17
Presentations at ID Week™ 2017 Highlight Clinical Results and Microbiome Analysis of Patients Treated in Rebiotix RBX2660 Phase 2 Studies
09.06.17
Rebiotix Appoints Edward S. Burd, Ph.D., to Head of Regulatory Affairs
08.23.17
Rebiotix to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference
08.07.17
Rebiotix Announces First Patient Enrolled in Phase 3 Clinical Trial of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection
06.20.17
Rebiotix Continues Management Team Expansion with Appointment of Greg Fluet as Chief Business Officer
06.07.17
Rebiotix Data Presented at ASM Microbe 2017 Show RBX2660 Treated Patients’ Clinical Success Correlates with Improved Microbiome Diversity
06.01.17
Rebiotix’s Phase 3-Ready RBX2660 to be Featured in Multiple Posters at ASM Microbe 2017
05.04.17
Rebiotix’s Phase 3 Ready RBX2660 to be Featured in Multiple Sessions at Digestive Disease Week 2017
04.11.17
Rebiotix Reports Positive Top Line Data from Open-Label Phase 2 Trial of RBX2660 in Recurrent Clostridium difficile
03.02.17
Rebiotix to Present at Two Investor Conferences
02.06.17
Rebiotix to Present at BIO CEO & Investor Conference
01.04.17
Rebiotix Treats First Patient in Phase 1 Study of RBX7455, an Orally Delivered Broad-Spectrum Non-Frozen Microbiota Capsule for Recurrent Clostridium difficile Infection
11.28.16
Rebiotix Appoints Ken F. Blount, Ph.D., Head of External Research
11.16.16
Rebiotix to Present at Piper Jaffray 28th Annual Healthcare Conference
10.17.16
Data from Rebiotix’s Phase 2b Trial of Lead Microbiota-Based Drug Candidate, RBX2660, to be Featured in Late-Breaking Oral Presentation at UEG Week 2016
10.11.16
Rebiotix Receives Patent from the USPTO for Microbiota Restoration Therapy
09.06.16
Rebiotix to Present at BioCentury’s 23rd Annual NewsMakers in the Biotech Industry Conference
01.11.16
Rebiotix and Washington University Treat First Patient with Urinary Tract Infection Utilizing Investigational RBX2660 to Potentially Reverse Multidrug Resistant Organisms
12.14.15
Rebiotix and McMaster Children’s Hospital Announce First Patient Treated in Largest Randomized Clinical Trial of Fecal Microbial Transplant (FMT) for Pediatric Ulcerative Colitis
12.01.15
Rebiotix Named 2015 Tekne Award Winner
11.18.15
Rebiotix Completes Enrollment in Phase 2 Trial of a Microbiota Restoration Therapy (MRT) for the Treatment of Recurrent Clostridium difficile Infection
10.12.15
Rebiotix Receives Breakthrough Therapy Designation for RBX2660 – A Microbiota Restoration Therapy (MRT) for the Treatment of Recurrent Clostridium difficile Infection
12.16.14
Rebiotix Announces First-Ever Randomized Study of a Microbiota-based Drug for Recurrent Clostridium difficile Infection under an FDA IND
10.20.14
Rebiotix Presents Additional Results of PUNCH™ CD Study of Microbiota-based Drug Candidate for Recurrent C. difficile Infection at ACG
10.09.14
Study Shows Rebiotix Microbiota-based Drug Candidate Targeted at Recurrent C. difficile Infection is Highly Effective
09.17.14
PUNCH™ CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014
08.04.14
Rebiotix Inc. Receives $25M for Series B Funding
06.03.14
Rebiotix to Present at 2014 BIO International Conference
01.13.14
Rebiotix Completes Enrollment in Phase 2 Clinical Trial of New Drug for the Treatment of Recurrent Clostridium difficile-Associated Diarrhea
10.31.13
Rebiotix Wins 2013 Leaders in Health Care Award
10.15.13
Rebiotix Begins Clinical Trial of Therapy for the Treatment of Recurrent Clostridium difficile-Associated Diarrhea
09.05.13
Rebiotix Named Finalist for 2013 Leaders in Health Care Awards
07.29.13
Rebiotix Receives FDA IND Approval to Begin Phase 2 Trial of Pioneering Microbiota Restoration Therapy
06.24.13
FDA Grants Fast Track Designation to Rebiotix for its Microbiota Product for Recurrent Clostridium difficile Infection
06.04.13
Rebiotix Inc. Hires Ryan Gordon as Vice President
05.01.13
Dr. William McGuire, Former UnitedHealth Group CEO, Joins Rebiotix Inc. Board of Directors
